Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcinosis Cutis in Sjögren's Syndrome With Interstitial Lung Disease.

International journal of rheumatic diseases·2026
Same author

Case Report: Successful Treatment of Refractory Relapsing Polychondritis with Anti-CD20 Therapies.

International journal of rheumatic diseases·2026
Same author

Predictors of damage accrual by organ domain in systemic lupus erythematosus.

Rheumatology (Oxford, England)·2025
Same author

Item selection for the development and validation of a revised classification criteria for adult and juvenile idiopathic inflammatory myopathies: MyoROC project.

Seminars in arthritis and rheumatism·2025
Same author

Clinical and Serological Correlates of Serum C1Q and Anti-C1Q Antibodies in South Africans With Systemic Lupus Erythematosus.

Journal of clinical laboratory analysis·2025
Same author

The TFIID complex is a new autoantibody target in systemic sclerosis.

Annals of the rheumatic diseases·2025

Related Experiment Video

Updated: Jul 1, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Lupus in the developing world--is it any different?

Mohammed Tikly1, Sandra V Navarra

  • 1Division of Rheumatology, Department of Medicine, Chris Hani Baragwanath Hospital and University of the Witwatersrand, P.O. Bertsham 2013, South Africa. tikly.mohammed01@gmail.com

Best Practice & Research. Clinical Rheumatology
|September 12, 2008
PubMed
Summary
This summary is machine-generated.

Systemic lupus erythematosus (SLE) presents differently worldwide, with higher severity and comorbidity in developing nations. Early interventions and resource-based treatment algorithms are crucial for improving survival rates in these regions.

Related Experiment Videos

Last Updated: Jul 1, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Area of Science:

  • Rheumatology
  • Global Health
  • Immunology

Background:

  • Systemic lupus erythematosus (SLE) affects global populations, exhibiting variations in disease severity and comorbidity between industrialized and developing regions.
  • While SLE clinical features are broadly similar, prevalence and severity differ, particularly in individuals of African and Asian descent.
  • Renal disease, discoid lupus, lymphopenia, and specific autoantibody profiles (e.g., anti-Sm, anti-U1RNP) show regional variations.

Purpose of the Study:

  • To analyze the global disparities in Systemic Lupus Erythematosus (SLE) presentation, severity, and outcomes.
  • To identify key factors contributing to morbidity and mortality in SLE patients across different socioeconomic settings.
  • To highlight the need for region-specific diagnostic and treatment strategies for SLE.

Main Methods:

  • Comparative analysis of SLE clinical features, prevalence, and outcomes across diverse geographical and socioeconomic populations.
  • Review of epidemiological data and clinical observations regarding SLE in developing versus industrialized countries.
  • Examination of comorbidity patterns, including infections and autoantibody profiles, in different SLE patient cohorts.

Main Results:

  • SLE is more common and severe in people of African and Asian descent, especially in industrialized countries.
  • Renal disease and infections (like tuberculosis) are major causes of morbidity and mortality in developing countries.
  • Thrombotic complications and anti-phospholipid antibodies are less frequent in Black African and Chinese SLE patients compared to Caucasians.
  • Survival rates for SLE patients are substantially lower in developing countries due to factors like infection and active disease.

Conclusions:

  • Significant disparities exist in SLE outcomes globally, with poorer prognosis in developing nations.
  • Genetic factors and resource limitations contribute to adverse outcomes, necessitating tailored healthcare approaches.
  • Improving SLE patient outcomes requires enhanced disease burden definition, public awareness, and adaptive diagnostic/treatment algorithms.